Literature DB >> 25924628

Prevalence and factors associated with isolation of Aspergillus and Candida from sputum in patients with non-cystic fibrosis bronchiectasis.

Luis Máiz1, Montserrat Vendrell, Casilda Olveira, Rosa Girón, Rosa Nieto, Miguel Ángel Martínez-García.   

Abstract

BACKGROUND: Information on the role of fungi in non-cystic fibrosis (CF) bronchiectasis is lacking.
OBJECTIVES: Our aim was to determine the prevalence of and factors associated with the isolation and persistence of fungi from sputum in these patients.
METHODS: We performed a multicenter observational study comprising adult patients with non-CF bronchiectasis. Persistence of Aspergillus spp. and Candida albicans was defined as the presence of ≥2 positive sputum cultures taken at least 6 months apart within a period of 5 years.
RESULTS: A total of 252 patients (62.7% women with a mean ± SD age of 55.3 ± 16.7 years) were included in the study. All patients had at least 1 sputum sample cultured for fungi, with a mean ± SD of 7 ± 6 cultures per patient. Eighteen (8.7%) and 71 (34.5%) patients had persistent positive cultures for Aspergillus spp. and C. albicans, respectively. Patients with persistence of Aspergillus spp. and C. albicans were older and had more daily purulent sputum. In addition, patients with persistent C. albicans had worse postbronchodilator forced expiratory volume in the first second (FEV1), more frequent cystic bronchiectasis, and more hospital-treated exacerbations. They were also more frequently treated with long-term antibiotics. Multivariate analysis showed that daily purulent sputum (OR = 3.75, p = 0.045) and long-term antibiotics (OR = 2.37, p = 0.005) were independently associated with persistence of Aspergillus spp. and C. albicans, respectively.
CONCLUSIONS: Isolation and persistence of Aspergillus spp. and C. albicans are frequent in patients with non-CF bronchiectasis. Daily purulent sputum and chronic antibiotic treatment were associated with persistence of Aspergillus spp. and C. albicans, respectively.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25924628     DOI: 10.1159/000381289

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  14 in total

Review 1.  Respiratory Mycoses in COPD and Bronchiectasis.

Authors:  Pei Yee Tiew; Micheál Mac Aogáin; Soo Kai Ter; Stefano Aliberti; James D Chalmers; Sanjay H Chotirmall
Journal:  Mycopathologia       Date:  2021-03-11       Impact factor: 2.574

Review 2.  Aspergillus fumigatus and Aspergillosis in 2019.

Authors:  Jean-Paul Latgé; Georgios Chamilos
Journal:  Clin Microbiol Rev       Date:  2019-11-13       Impact factor: 26.132

Review 3.  Clinical Aspergillus Signatures in COPD and Bronchiectasis.

Authors:  Pei Yee Tiew; Kai Xian Thng; Sanjay H Chotirmall
Journal:  J Fungi (Basel)       Date:  2022-05-05

Review 4.  Aspergillus Species in Bronchiectasis: Challenges in the Cystic Fibrosis and Non-cystic Fibrosis Airways.

Authors:  Sanjay H Chotirmall; Maria Teresa Martin-Gomez
Journal:  Mycopathologia       Date:  2017-05-17       Impact factor: 2.574

5.  Sensitization to Aspergillus fumigatus as a risk factor for bronchiectasis in COPD.

Authors:  Stephanie Everaerts; Katrien Lagrou; Adriana Dubbeldam; Natalie Lorent; Kristina Vermeersch; Erna Van Hoeyveld; Xavier Bossuyt; Lieven J Dupont; Bart M Vanaudenaerde; Wim Janssens
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-08-31

Review 6.  Fungi in Bronchiectasis: A Concise Review.

Authors:  Luis Máiz; Rosa Nieto; Rafael Cantón; Elia Gómez G de la Pedrosa; Miguel Ángel Martinez-García
Journal:  Int J Mol Sci       Date:  2018-01-04       Impact factor: 5.923

Review 7.  Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasis.

Authors:  Ravishankar Chandrasekaran; Micheál Mac Aogáin; James D Chalmers; Stuart J Elborn; Sanjay H Chotirmall
Journal:  BMC Pulm Med       Date:  2018-05-22       Impact factor: 3.317

Review 8.  Pathogenesis, imaging and clinical characteristics of CF and non-CF bronchiectasis.

Authors:  Jürgen Schäfer; Matthias Griese; Ravishankar Chandrasekaran; Sanjay H Chotirmall; Dominik Hartl
Journal:  BMC Pulm Med       Date:  2018-05-22       Impact factor: 3.317

Review 9.  Why, when and how to investigate primary ciliary dyskinesia in adult patients with bronchiectasis.

Authors:  Martina Contarini; Amelia Shoemark; Jessica Rademacher; Simon Finch; Andrea Gramegna; Michele Gaffuri; Luca Roncoroni; Manuela Seia; Felix C Ringshausen; Tobias Welte; Francesco Blasi; Stefano Aliberti; James D Chalmers
Journal:  Multidiscip Respir Med       Date:  2018-08-09

10.  Increased Incidence and Associated Risk Factors of Aspergillosis in Patients with Bronchiectasis.

Authors:  Bumhee Yang; Taehee Kim; Jiin Ryu; Hye Yun Park; Bin Hwangbo; Sun-Young Kong; Yong-Soo Kwon; Seung Jun Lee; Seung Won Ra; Yeon-Mok Oh; Jang Won Sohn; Kang Hyeon Choe; Hayoung Choi; Hyun Lee
Journal:  J Pers Med       Date:  2021-05-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.